The CIRC has made it easier for insurance companies to engage in M&A. Although the Commission maintains a strict supervisory role in transactions, its motive for deregulation is clear. More reforms are in the pipeline for this complex and competitive market
Though the revised Trademark Law has made substantial improvements, protection and enforcement tactics against trademark squatters still remain crucial in the IP environment of China
Awareness of local courts and judges' practices as well as understanding of the laws, judicial trends and case outcomes are critical for MNCs' IP protection in China
The Supreme People's Court has released its report on the leading IP cases of 2013. The judges have clarified some issues but left important questions about the new procedural rules unanswered
The new Implementing Regulations fail to pick up on the many issues raised by the revised Trademark Law, such as clarifying OEM limits, enforcing against those who facilitate infringement, calculating illegal operations and questioning the legitimacy of “good faith” sellers, says Jack Chang
I am looking to set up my business in China. There are many concerns among foreign investors regarding both onshore and offshore franchising. Should I enter into a direct contract with a local entity or form a joint venture? How do I ensure my assets will be protected?
The Environmental Protection Law has just been amended for the first time after 25 years. Conducting environmental due diligence and establishing an image of integrity are more important than ever for foreign enterprises
The Environmental Protection Law has just been amended for the first time after 25 years. Conducting environmental due diligence and establishing an image of integrity are more important than ever for foreign enterprises
GlaxoSmithKline is facing serious charges of misconduct as enforcement grows fierce. The entwining Chinese anti-bribery laws, the US FCPA and UK Bribery Act call for immediate attention to risks and compliance on both a national and global scale
GlaxoSmithKline is facing serious charges of misconduct as enforcement grows fierce. The entwining Chinese anti-bribery laws, the US FCPA and UK Bribery Act call for immediate attention to risks and compliance on both a national and global scale